Search the Newsreel

Pacer Advisors Inc. Sells 17,967 Shares of Coca-Cola Europacific Partners $CCEP

Pacer Advisors Inc. reduced its stake in Coca-Cola Europacific Partners (NASDAQ:CCEP) by 51.1% in the first quarter, selling 17,967 shares and retaining 17,179 shares valued at $1.56 million. Despite this reduction, other institutional investors have increased their holdings, with hedge funds and institutions collectively …

WaveDancer, Inc. Releases 2023 10-K Report Highlighting Strategic Shifts and Financial Performance

WaveDancer, Inc. has released its 2023 Form 10-K report, detailing a 27.6% revenue decrease to $8.0 million, alongside a significant reduction in net loss to $2.0 million. The company is strategically shifting its focus from IT consulting towards AI-driven Brain Network Analytics through a …

European Innovation Solutions S.A. Revenue Breakdown – ATHEX:EIS

Euroholdings Ltd Announces 2026 Annual Meeting of Shareholders

Euroholdings Ltd (NASDAQ: EHLD) has scheduled its Annual Meeting of Shareholders for July 23, 2026, in Maroussi, Greece. Shareholders of record by June 16, 2026, will be eligible to participate. The agenda includes electing two Class B directors and ratifying Deloitte as the independent …

Value Retail Stocks That Could Benefit As Wages Finally Outpace Inflation

EuroDry (NASDAQ:EDRY) Releases Earnings Results, Beats Estimates By $1.21 EPS

EuroDry (NASDAQ:EDRY) announced its quarterly earnings, significantly beating analyst estimates with an EPS of $2.44, surpassing the consensus by $1.21. Revenue increased by 57% year-over-year to $17.7 million. The company showcased strong operating performance with 100% fleet utilization and more than doubled time charter …

Best Momentum Stocks to Buy for August 7th

This article identifies three top momentum stocks for August 7th: EuroDry Ltd. (EDRY), Columbus McKinnon Corporation (CMCO), and OP Bancorp (OPBK). Each company holds a Zacks Rank #1 (Strong Buy) and has shown significant earnings estimate revisions and stock price gains over the last …

Euro Tech Holdings Company Ltd (CLWT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen

Wall Street Zen upgraded Minerva Neurosciences (NASDAQ:NERV) from a "sell" to a "hold" rating. The biopharmaceutical company reported a quarterly loss of $0.14 per share, surpassing analyst expectations for a $0.19 loss. Despite the upgrade, NERV shares were trading down 3.8% at $4.27, well …

Reinhart Partners LLC. Buys 136,613 Shares of Euronet Worldwide, Inc. $EEFT

Reinhart Partners LLC increased its stake in Euronet Worldwide, Inc. by 9.2%, acquiring 136,613 additional shares to reach a total of 1.63 million shares valued at $119.1 million. Institutional investors now own 91.6% of the company, while director Thomas A. McDonnell also purchased 3,000 …

NeuroPace, Inc. expected to post a loss of 21 cents a share - Earnings Preview

NeuroPace, Inc. is projected to report a loss of 21 cents per share, according to this earnings preview. The article indicates that this financial outlook is based on information from Refinitiv. Full article access requires a TradingView subscription.

North European Oil Royality Trust (NYSE:NRT) Share Price Crosses Above 200 Day Moving Average - Here's Why

North European Oil Royality Trust (NRT) shares have risen above their 200-day moving average, trading as high as $8.87, significantly above the $8.37 average. This occurred after the trust reported quarterly EPS of $0.22 on $2.38 million in revenue and increased its quarterly dividend …

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers significantly increased its stake in Neurocrine Biosciences (NBIX) by 50.1% in the first quarter, now owning 20,245 shares valued at $2.67 million. Institutional investors hold 92.59% of NBIX. Despite insider sales totaling over $62 million in the past quarter, analysts maintain …

Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-08-07

This article announces that Neurocrine Biosciences, Inc. (NBIX) has published its slide deck in conjunction with its Q2 2026 earnings call. The earnings call presentation was made on August 7, 2026. The article was written by the Seeking Alpha Transcripts team, which regularly publishes …

Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC

PKO BP BANKOWY Universal Pension Society JSC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 23.1% in the second quarter, now holding 170,802 shares valued at $28.8 million. This move highlights continued institutional investor interest, with several other hedge funds also boosting their …

Form 8K Minerva Neurosciences Inc For: 7 August By Investing.com

This article reports on the filing of a Form 8K by Minerva Neurosciences Inc. on August 7. It includes a brief mention of the company's stock symbol and a slight decrease in its share price. The content primarily serves as an announcement for the …

Minerva Neurosciences posts Q2 2026 results: GAAP net income $17.5M; cash & equivalents $75.4M

Minerva Neurosciences reported a GAAP net income of $17.5 million for Q2 2026, largely due to a non-cash gain on a warrant liability, with cash and equivalents standing at $75.4 million. The company is advancing a global confirmatory Phase 3 trial for roluperidone, with …

Enterprise value to EBIT forward of Neuropace, Inc. – NASDAQ:NPCE

This article provides a financial data point for Neuropace, Inc. (NASDAQ: NPCE), specifically its enterprise value to EBIT forward. It appears to be a financial snapshot from TradingView, indicating the company's financial metrics. The content is sparse, primarily focusing on this single financial ratio …

ETFs Investing in Neurocrine Biosciences, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Neurocrine Biosciences, Inc. The list, sorted by market value, provides details such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV …

How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors

Neurocrine Biosciences recently reported strong Q2 2026 results, with significant revenue and net income, alongside a new equity shelf registration tied to an ESOP offering. This dual development highlights the company's efforts to strengthen employee ownership and financial flexibility. The article discusses how these …

ClearPoint Neuro (NASDAQ:CLPT) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded ClearPoint Neuro (NASDAQ:CLPT) to a "strong sell" rating, despite other analysts having a mixed view with a consensus "Hold" rating and a target price of $25.67. The downgrade follows ClearPoint Neuro missing its quarterly earnings expectations, reporting an adjusted …

Euroseas Ltd (ESEA) Stock News Today

This article provides current stock information for Euroseas Ltd (ESEA), including its latest closing price, after-hours trading, market capitalization, and P/E ratio. It highlights that more news for ESEA is expected soon. The page serves as a hub for financial data and news updates …

Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Clearpoint Neuro Inc (CLPT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Alto Neuroscience Inc (ANRO), detailing analyst ratings and EPS expectations. Ten analysts currently rate ANRO as a "Strong Buy" with a target price indicating a potential 24.11% upside. The previous quarter's EPS was -$0.47, beating the market …

EuroDry Ltd (EDRY) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for EuroDry Ltd (EDRY), indicating a current earnings forecast score of 8.00 and ranking 14th in the Freight & Logistics Services industry. Analysts have set an average price target of $20.00, with a "Buy" rating based on 3 …

EuroDry (EDRY) Stock Reprices As Profit Return Meets Book Value Ceiling

EuroDry (EDRY) stock jumped 16% after reporting a strong Q2 2026, turning a profit of US$6.6m on US$17.7m revenue and US$2.36 EPS, a significant turnaround from previous losses. The share price is now close to its book value per share of US$34.90, reflecting market …

Noticias de acciones de Coca-Cola Europacific Partners PLC (CCEP)

European Lithium's Merger Countdown: A Five-Percent Stake, a $296 Million Cushion, and a September D

Euro Tech Holdings Company Ltd (CLWT) Stock News Today

XBP Europe Holdings Inc (XBP) Stock News Today

Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed stock information for Neurocrine Biosciences, Inc. (NBIX), including its current price, historical data, financial performance, analyst ratings, and company overview. It highlights key products like INGREZZA and several pipeline candidates for neurological and psychiatric disorders. The company's market …

Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview

Neuronetics Inc is projected to report a loss of 12 cents per share, according to an earnings preview. The article, sourced from Reuters, provides this financial expectation. Readers can access the full article through TradingView.

Firefly Neuroscience (NASDAQ: AIFF) slashes authorized shares to 101M

Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Jupiter Neurosciences Inc (JUNS), indicating that no earnings forecast score is currently available, while the industry average is 8.10. Based on one analyst, the stock has a "Buy" rating with a target price of 25.000, representing 0.00% …

Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts

Promis Neurosciences (NASDAQ:PMN) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $31.50. Despite this positive outlook, the company reported a quarterly loss of $1.26 per share, missing consensus estimates, and analysts anticipate a full-year loss …